Status:
RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least on...
Eligibility Criteria
Inclusion
- Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
- Have an increased waist to height ratio (defined by \>0.5)
- Have at least one weight related comorbid condition
- Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)
Exclusion
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Key Trial Info
Start Date :
November 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2032
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT07247084
Start Date
November 24 2025
End Date
July 1 2032
Last Update
March 6 2026
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
P91604 St John's Medical Centre
Altrincham, United Kingdom, WA14 1PF
2
P89008 Ashton Medical Group
Ashton-under-Lyne, United Kingdom, OL6 6EW
3
Y02319 SSP Bolton General Practice
Bolton, United Kingdom, BL1 4TH
4
P83012 Tower Family Healthcare
Bury, United Kingdom, BL9 0NJ